1. Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical Tenofovir.
- Author
-
Noguchi LM, Montgomery ET, Biggio JR, Hendrix CW, Bogen DL, Hillier SL, Dai JY, Piper JM, Marzinke MA, Dezzutti CS, Isaacs SK, Schwartz JL, Watts DH, and Beigi RH
- Subjects
- Adult, Breast Feeding, Female, HIV Infections blood, HIV Infections drug therapy, HIV Infections metabolism, HIV-1 drug effects, Humans, Infant, Lactation metabolism, Mothers, Tenofovir therapeutic use, Vaginal Creams, Foams, and Jellies pharmacokinetics, Vaginal Creams, Foams, and Jellies therapeutic use, Young Adult, Anti-HIV Agents blood, Milk, Human metabolism, Tenofovir blood, Tenofovir pharmacokinetics
- Abstract
Lactation studies are necessary evaluations of medications for reproductive-age women. We evaluated pharmacokinetics (PK), pharmacodynamics, safety, and adherence profiles associated with 7 days of 1% tenofovir (TFV) vaginal gel use during lactation. Tenofovir levels (maternal/infant serum, milk) and anti-HIV activity (milk), adverse events (AEs), and adherence were measured for 17 HIV-1-seronegative breast-feeding mother-infant pairs. Tenofovir use was well-tolerated and detected at low levels in maternal serum, milk, and infant serum but demonstrated no anti-HIV activity in milk., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Published
- 2016
- Full Text
- View/download PDF